127943-83-3

Upstream product

• 1484-26-0 3-(benzyloxy)aniline 
• 55120-56-4 4-bromo-3-hydroxy-aniline 
• 144-55-8 sodium hydrogencarbonate 
• 100-44-7 benzyl chloride 
• 6345-68-2 2-(benzyloxy)-1-bromo-4-nitrobenzene 
• 100-51-6 benzyl alcohol 
• 185331-69-5 1-bromo-2-fluoro-4-nitrobenzene 

Relevant academic research and scientific papers

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.

Quinoline derivatives

Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Synthesis of N-(phenylsulfonyl)-CI, N-((tert-butyloxy)carbonyl)-CI, CI-CDPI 1, and CI-CDPI 2: CC-1065 functional analogues incorporating the parent 1,2,7,7a-tetrahydrocycloprop[1,2-c]indol-4-one (CI) left-hand subunit

Full details of the synthesis of N-(phenylsulfonyl)- and N-((tert-butyloxy)carbonyl)-1,2,7,7a-tetrahydrocycloprop[1,2-c]indol-4-one [N-(phenylsulfonyl)-CI (9) and N-BOC-CI (10)] constituting stable derivatives of the parent cyclopropylcyclohexadienone rin